Monograph
A10BA02 - Metformin |
Not porphyrinogenic |
NP |
Rationale
Metformin is not metabolized in the body. The physiological effects are not porphyrinogenic. Nausea and vomiting may be potentially porphyrinogenic through reduced caloric intake, but can be counteracted by suitable administration regimes. More than 30 observations of safe use by carriers of acute porphyria.
Chemical description
Biguanide antidiabetic.
Therapeutic characteristics
Metformin is indicated for the improvement of glycaemic control in adult patients with type 2 diabetes mellitus. It is administered orally. Common adverse reactions of metformin that can be confused with an acute porphyric attack are nausea, vomiting and abdominal pain.
Metabolism and pharmacokinetics
Eliminated unchanged via glomerular filtration.
Published experience
Kauppinen 1992: uneventfully used by one patient with acute porphyria.
IPNet drug reports
Uneventful use reported in 30 patients with acute porphyria.
References
| # |
Citation details |
PMID |
|---|
| * | Scientific articles |
| 1. |
Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore). 1992 Jan; 71(1):1-13.
Kauppinen R, Mustajoki P. |
1549056 |
| 2. |
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.
Tornio A, Niemi M, et al. Trends Pharmacol Sci. 2012 Jun; 33(6):312-22. |
22475684 |
| * | Summary of Product Characteristics |
| 3. |
The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Glucophage.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
